Clinical Trials on Neurofibroma, Plexiform in United States

Total 213 results

University of Pittsburgh
National Cancer Institute (NCI)

Completed

Study of PEG-Intron for Plexiform Neurofibromas

Plexiform Neurofibroma

United States
Children's National Research Institute

Active, not recruiting

Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1

Neurofibromatosis 1 | Neurofibroma | Plexiform Neurofibroma | Atypical Neurofibroma | Atypical Neurofibromatosis | Von Recklinghausen Disease

United States
National Cancer Institute (NCI)

Completed

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Plexiform Neurofibroma | Neurofibromatosis Type I

United States
National Cancer Institute (NCI)

Active, not recruiting

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Neurofibromatosis 1 (NF1) | Plexiform Neurofibromas (PN)

United States
National Cancer Institute (NCI)

Terminated

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Neurofibromatosis Type 1 | Plexiform Neurofibroma | Spinal Cord Neurofibroma

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

Unspecified Childhood Solid Tumor, Protocol Specific | Neoplasm of Uncertain Malignant Potential

United States
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)

Neurofibromatosis 1 | Plexiform Neurofibroma (PN)

United States, Canada, France, Italy, Germany, China, United Kingdom, Spain, Japan, Russian Federation, Australia, Poland, Brazil
AstraZeneca

Approved for marketing

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

NF type1 With Inoperable Plexiform Neurofibromas

United States
University of Alabama at Birmingham
Pacific Pediatric Neuro-Oncology Consortium; Array BioPharma

Active, not recruiting

Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas (NF108-BINI)

Neurofibromatosis Type 1 | Plexiform Neurofibroma

United States
AstraZeneca

Completed

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

Healthy Participants | Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)

United States
Spectrum Health Hospitals
Van Andel Research Institute

Recruiting

Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.

Neurofibromatosis Type 1 | Plexiform Neurofibromas | Cutaneous Neurofibromas

United States
Kent Robertson

Completed

Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas (0908-09)

Neurofibromatosis | Neurofibromas

United States
Children's Hospital of Philadelphia
United States Department of Defense

Terminated

Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas (PDT)

Neurofibroma

United States
National Cancer Institute (NCI)

Completed

Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development

Cancer

United States
Shanghai Fosun Pharmaceutical Industrial Development...

Active, not recruiting

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Neurofibromatosis 1 | NF1 | Plexiform Neurofibroma

United States, China, Spain
SpringWorks Therapeutics, Inc.

Active, not recruiting

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas (ReNeu)

Plexiform Neurofibroma | Neurofibromatosis Type 1 (NF1)

United States
Indiana University
Novartis

Completed

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Neurofibromatosis | NF1 | Neurofibromas

United States
Alexion

Recruiting

US Selumetinib Registry

Neurofibromatosis Type 1 | Plexiform Neurofibromas

United States
National Cancer Institute (NCI)

Completed

Study of Plexiform Neurofibromas in Neurofibromatosis Type 1

Plexiform Neurofibromas | NF1

United States
Indiana University
Pfizer; United States Department of Defense

Terminated

Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas

Neurofibromatosis | Plexiform Neurofibromas | NF1

United States
National Cancer Institute (NCI)

Completed

Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain

Neurofibromatosis Type 1 | Plexiform Neurofibromas

United States
National Cancer Institute (NCI)

Recruiting

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)

Neurofibromatosis 1 | Plexiform Neurofibromas

United States
Children's Hospital of Philadelphia

Completed

Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas

Neurofibromatosis Type 1 | Precancerous Condition

United States
Children's Hospital of Philadelphia

Terminated

Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma

Neurofibromatosis Type 1 | Precancerous Condition

United States
University of Alabama at Birmingham

Completed

Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults (NF105-CABO)

Neurofibromatosis | Plexiform Neurofibromas | NF1

United States
National Cancer Institute (NCI)

Completed

Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial

Neurofibromatosis 1

United States
Indiana University

Completed

Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Neurofibromatosis

United States
Great Ormond Street Hospital for Children NHS Foundation...
AstraZeneca

Completed

Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours (INSPECT)

Neurofibromatosis Type 1 | Optic Nerve Glioma | Plexiform Neurofibroma

United Kingdom
Novartis Pharmaceuticals

Completed

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Cancer

France, Australia, United States, Canada, United Kingdom
UNC Lineberger Comprehensive Cancer Center

Completed

PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)

Optic Glioma | Plexiform Neurofibroma | Neurofibromatosis-1

United States
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Neurofibromatosis Type 1

United States, Spain, Poland, Russian Federation
National Cancer Institute (NCI)

Active, not recruiting

Natural History Study of Patients With Neurofibromatosis Type I

Neurofibroma | Neurofibromatosis Type 1 | Malignant Peripheral Nerve Sheath Tumor | Optic Glioma | Plexiform Neurofibroma

United States
University of Alabama at Birmingham
National Cancer Institute (NCI); Children's Hospital of Philadelphia; Washington... and other collaborators

Completed

A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas (Protocol 102)

Neurofibromatosis Type 1

United States
National Cancer Institute (NCI)

Completed

Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas

Neurofibromatosis Type 1 | Precancerous Condition

United States
National Cancer Institute (NCI)

Completed

Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

Neurofibromatosis | MPNST

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Avutometinib for People With Solid Tumor Cancers

Solid Tumor | Neuroblastoma | Solid Tumor, Adult | Primary Brain Tumor | Solid Carcinoma | Low-grade Glioma | Central Nervous System Tumor | Refractory Cancer | CNS Tumor, Adult | CNS Tumors | NF1 | Plexiform Neurofibroma | CNS Tumor, Childhood | Optic Pathway Gliomas | MAP Kinase Family Gene Mutation

United States
Indiana University

Withdrawn

Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Neurofibroma, Plexiform

United States
National Cancer Institute (NCI)

Completed

Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)

Neurofibromatosis 1 | Peripheral Nerve Neoplasms, Malignant

United States
National Cancer Institute (NCI)

Completed

Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

Neurofibromatosis 1 | Neurofibroma, Plexiform

United States
National Cancer Institute (NCI)

Completed

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Neurofibroma, Plexiform | Neurofibromatosis Type I

United States, Germany
National Cancer Institute (NCI)

Withdrawn

Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics

Neoplasms | Myelodysplastic Syndromes | Adenomatous Polyposis Coli | Neurofibroma, Plexiform

United States
National Cancer Institute (NCI)

Completed

Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials

Neurofibromatosis 1 | Neurofibroma, Plexiform

United States
Nicholas Gulati

Active, not recruiting

DPCP to Treat Cutaneous Neurofibromas Associated With NF1

Cutaneous Neurofibroma

United States
Johns Hopkins University
Neurofibromatosis Therapeutic Acceleration Program

Recruiting

Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). (Mirda)

Cutaneous Neurofibroma | NF1 | Monotherapy

United States
National Cancer Institute (NCI)

Active, not recruiting

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Neurofibromatosis 1 | Neurofibroma, Plexiform | Neurofibromatosis Type 1 | NF1

United States
Massachusetts General Hospital
Johns Hopkins University

Not yet recruiting

Assessing the Efficacy of Repeat, Monthly Treatments of Cutaneous Neurofibromas (cNFs)

Neurofibromatosis 1 | Neurofibromas, Cutaneous

United States
Massachusetts General Hospital

Completed

Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1

Neurofibromatosis Type 1 | Cutaneous Neurofibromas

United States
Massachusetts General Hospital
Johns Hopkins University

Active, not recruiting

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas

Cutaneous Neurofibroma

United States
National Cancer Institute (NCI)

Recruiting

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

Sarcoma | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Neurofibroma, Plexiform | Leukemia, Promyelocytic, Acute

United States
Johns Hopkins University
Neurofibromatosis Therapeutic Acceleration Program

Recruiting

Natural History Study of Cutaneous Neurofibromas in People With NF1 (cNF Natural Hx)

Neurofibromatosis 1 | Neurofibromatosis Type 1 | Cutaneous Neurofibroma | Neurofibromatosis (Nonmalignant)

United States

Clinical Trials on Neurofibroma, Plexiform in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations